Khaitan & Co Mumbai corporate partner Bhavik Narsana led the transaction with inputs on specific issues from corporate partner Rabindra Jhunjhunwala, banking partner Devidas Banerji, litigation partner Chakrapani Misra, partners Sudip Mullick and Abhishek Sharma on real estate, with competition law counsel Avaantika Kakkar, tax executive directors Daksha Baxi and Dinesh Agarwal and principal associate Adheesh Nargolkar, in acting for OPF which is Japanese diversified healthcare group Otsuka’s originating company.

Herbert Smith Freehills Tokyo partner James Robinson also acted for OPF.

AZB & Partners Mumbai partner Abhijit Joshi with associates Nilanjana Singh and Adarsh Varghese acted for the Ahmedabad-based Claris Lifesciences which is India’s largest injectable drugs maker and which entered into the JV through its subsidiary Claris Specialty Injectibles.

Amarchand Mangaldas Delhi partner Amit Kumar with principal associate Saurav Kumar and senior associate Ambarish acted for Mitsui & Co which is Japan’s largest general trading company.

Claris Lifesciences and Mitsui & Co will hold 20 per cent each, while OPF will hold 60 per cent in the JV Claris Specialty Injectibles, according to the Economic Times.

The JV will help introduce Otsuka’s products for the first time to the Indian drugs market, according to DNA India.

Photo credits: Ein86